Yupeng Feng

Yupeng Feng

Auto-generated profile, based on publicly available information

Yupeng Feng

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
PAPrabhu Arunachalam
Prabhu Arunachalam
FWFlorian Wimmers
Florian Wimmers
CMChris Ka Pun Mok
Chris Ka Pun Mok
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
MSMadeleine Scott
Madeleine Scott
BPBali Pulendran
Bali Pulendran
Immune profiling of COVID-19 patients: Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathewet al.present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalamet al.report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions.Science, this issue p.eabc8511, p.1210

12 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PAPrabhu Arunachalam
Prabhu Arunachalam
MSMadeleine K. D. Scott
Madeleine K. D. Scott
THThomas Hagan
Thomas Hagan
CLChunfeng Li
Chunfeng Li
YFYupeng Feng
Yupeng Feng
BPBali Pulendran
Bali Pulendran

14 March 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CLChunfeng Li
Chunfeng Li
ALAudrey Lee
Audrey Lee
LGLilit Grigoryan
Lilit Grigoryan
PAPrabhu Arunachalam
Prabhu Arunachalam
MSMadeleine K. D. Scott
Madeleine K. D. Scott
BPBali Pulendran
Bali Pulendran

28 December 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
WLWei Luo
Wei Luo
JAJulia Z. Adamska
Julia Z. Adamska
CLChunfeng Li
Chunfeng Li
RVRohit Verma
Rohit Verma
QLQing Liu
Qing Liu
BPBali Pulendran
Bali Pulendran

10 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
YFYupeng Feng
Yupeng Feng
MYMeng Yuan
Meng Yuan
JPJohn M. Powers
John M. Powers
MHMengyun Hu
Mengyun Hu
JMJennifer E. Munt
Jennifer E. Munt
BPBali Pulendran
Bali Pulendran
The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development of countermeasures that provide broad protection against SARS-CoV-2 and related sarbecoviruses. Here, we identified extremely potent monoclonal antibodies (mAbs) that neutralized multiple sarbecoviruses from macaques vaccinated with AS03-adjuvanted monovalent subunit vaccines. Longitudinal analysis revealed progressive accumulation of somatic mutation in the immunoglobulin genes of antigen-specific memory B cells (MBCs) for at least 1 year after primary vaccination. Antibodies generated from these antigen-specific MBCs at 5 to 12 months after vaccination displayed greater potency and breadth relative to those identified at 1.4 months. Fifteen of the 338 (about 4.4%) antibodies isolated at 1.4 to 6 months after the primary vaccination showed potency against SARS-CoV-2 BA.1, despite the absence of serum BA.1 neutralization. 25F9 and 20A7 neutralized authentic clade 1 sarbecoviruses (SARS-CoV, WIV-1, SHC014, SARS-CoV-2 D614G, BA.1, and Pangolin-GD) and vesicular stomatitis virus–pseudotyped clade 3 sarbecoviruses (BtKY72 and PRD-0038). 20A7 and 27A12 showed potent neutralization against all SARS-CoV-2 variants and multiple Omicron sublineages, including BA.1, BA.2, BA.3, BA.4/5, BQ.1, BQ.1.1, and XBB. Crystallography studies revealed the molecular basis of broad and potent neutralization through targeting conserved sites within the RBD. Prophylactic protection of 25F9, 20A7, and 27A12 was confirmed in mice, and administration of 25F9 particularly provided complete protection against SARS-CoV-2, BA.1, SARS-CoV, and SHC014 challenge. These data underscore the extremely potent and broad activity of these mAbs against sarbecoviruses.

23 May 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
LGLilit Grigoryan
Lilit Grigoryan
ALAudrey Lee
Audrey Lee
AWAlexandra C. Walls
Alexandra C. Walls
LLLilin Lai
Lilin Lai
BFBenjamin Franco
Benjamin Franco
BPBali Pulendran
Bali Pulendran
Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by leading adjuvant candidates. In this study, we compared five clinically relevant adjuvants in mice—alum, AS03 (a squalene-based adjuvant supplemented with α-tocopherol), AS37 (a TLR7 ligand emulsified in alum), CpG1018 (a TLR9 ligand emulsified in alum), O/W 1849101 (a squalene-based adjuvant)—for their capacity to stimulate immune responses when combined with a subunit vaccine under clinical development. We found that all four of the adjuvant candidates surpassed alum with respect to their capacity to induce enhanced and durable antigen-specific antibody responses. The TLR-agonist-based adjuvants CpG1018 (TLR9) and AS37 (TLR7) induced Th1-skewed CD4+ T cell responses, while alum, O/W, and AS03 induced a balanced Th1/Th2 response. Consistent with this, adjuvants induced distinct patterns of early innate responses. Finally, vaccines adjuvanted with AS03, AS37, and CpG1018/alum-induced durable neutralizing-antibody responses and significant protection against the B.1.351 variant 7 months following immunization. These results, together with our recent results from an identical study in non-human primates (NHPs), provide a comparative benchmarking of five clinically relevant vaccine adjuvants for their capacity to stimulate immunity to a subunit vaccine, demonstrating the capacity of adjuvanted SARS-CoV-2 subunit vaccines to provide durable protection against the B.1.351 variant. Furthermore, these results reveal differences between the widely-used C57BL/6 mouse strain and NHP animal models, highlighting the importance of species selection for future vaccine and adjuvant studies.